Citi Bonus Zert BAYN 24.12.2024/ DE000KJ1W885 /
14/08/2024 19:27:21 | Chg.-0.100 | Bid21:58:17 | Ask- | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
25.740EUR | -0.39% | 25.660 Bid Size: 500 |
- Ask Size: - |
BAYER AG NA O.N. | - EUR | 24/12/2024 | Call |
GlobeNewswire
30/05
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
30/05
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
28/05
Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
GlobeNewswire
02/05
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
18/04
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
16/04
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
11/04
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
25/03
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
06/03
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
04/03
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
15/02
2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire
13/02
Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire
13/02
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
GlobeNewswire
05/01
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)